TK
Takeda Pharmaceutical Company Limited
TKPHF · OTC
$36.20 +2.43% (+$0.86)
1M +3.90%
Market Cap ¥8.68T
P/E Ratio 48.07x
Div. Yield 3.69%
ROE 2.40%
Bulios Fair Price
$41
13.3% upside
Current Price
$36.2
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TKPHF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
71 /100
Cheap EV/EBITDA 10.02x
P/S 1.88x
P/B 1.15x
Growth
45 /100
Stable Rev. growth 4.03%
FCF growth 30.74%
Book val. growth 7.18%
Profitability
66 /100
Moderate Net margin 3.90%
Op. margin 10.98%
FCF margin 15.14%
Quality
12 /100
Poor ROE 2.40%
ROA 1.15%
Asset turnover 0.30x
Debt
46 /100
Moderate Current ratio 1.14x
Int. coverage 2.04x
Net debt/EBITDA 3.41x
Stability
49 /100
Moderate Rev. volatility 4.51%
EPS volatility 70.07%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TKPHF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Julie So-Young Kim
Employees
47,029
Headquarters
Tokyo
Upcoming events
29 SEP
Ex-Dividend
Ex-dividend date
29 SEP
Dividend Payment
Payment date
29 OCT
Earnings
Upcoming earnings report
30 MAR
Ex-Dividend
Ex-dividend date
30 MAR
Dividend Payment
Payment date